Cancer Chemotherapy by Novel Bio-active Natural Products: Looking Towards the Future

Author(s): Om Prakash*, Shazia Usmani, Ruchi Singh, Debarshi K. Mahapatra, Amresh Gupta.

Journal Name: Current Cancer Therapy Reviews

Volume 15 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Cancer is the second leading cause of death globally and accounted for 8.8 million deaths annually in humans. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervix and stomach cancer are the most common among women. Numerous drugs that the US Food and Drug Administration (FDA) have approved for use in cancer therapy are derived from plants, including taxanes such as paclitaxel and vinca alkaloids such as vincristine and vinblastine. Still, there is an intense need for a search for numerous bioactive sources to develop a novel anti-cancer drug to overcome this chronic disorder. About more than thirty plants derived natural products have been isolated till date and are currently under clinical trials. As per literature survey from various journals and texts has been found to be novel medicinal agents from bioactive sources are clinically active against various types of cancer cells.

Conclusion: Current review has been highlighted on the novel medicinal agents from plant sources have potential effects against many types of cancer, which have been supported by clinical trials. The main findings of these active novel medicinal agents were also summarized and discussed here.

Keywords: Anti-cancer, herbal, natural product, chemotherapy, plant, review.

[1]
World Health Organization. Media centre: Cancer. Available at:. http://www. who.int/mediacentre/factsheets/fs297/en Accessed On: 10 October 2017.
[2]
Mahapatra DK, Bharti SK, Asati V. Anti-cancer chalcones: Structural and molecular target perspectives. Eur J Med Chem 2015; 98: 69-114.
[3]
Hardeland R. Melatonin in plants – diversity of levels and multiplicity of functions. Melatonin in plants – diversity of levels and multiplicity of functions. Front Plant Sci 2016; 7: 1-14.
[4]
Meng X, Li Y, Li S, et al. Dietary sources and bioactivities of melatonin. Nutr 2017; 9(4): 1-64.
[5]
Chuffa LGA, Reiter RJ, Lupi LA. Melatonin as a promising agent to treat ovarian Cancer: Molecular mechanisms. Carcinog 2017; 38: 945-52.
[6]
Chuffa LGA, Alves MS, Martinez M, et al. Apoptosis is triggered by melatonin in an in-vivo model of ovarian Carcinoma. Endocr Relat Cancer 2016; 23: 65-76.
[7]
Colombo J, Jardim PBV, Ferreira JPS, et al. Melatonin differentially modulates NF-KB expression in breast and liver cancer cells Anticancer Agents Med Chem 2018; 18: doi 10.2174/187152061 86661 80131112304..
[8]
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
[9]
Prakash O, Amit K, Pawan K, et al. anticancer potential of plants and natural products: A review. Am J Pharmacol Sci 2013; 1(6): 104-15.
[10]
Asati V, Mahapatra DK, Bharti SK. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem 2016; 109: 314-41.
[11]
Donaldron MS. Nutrition and cancer - A review of the evidence for an anticancer diet. Nutr J 2004; 3: 1-21.
[12]
Riboli E, Norat T. Epidemiological evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003; 78(3): 559-69.
[13]
Nichenametla SN, Taruscio TG, Barney DL, et al. A review of the effects and mechanisms of polyphenolics in cancer. Crit Rev Food Sci Nutr 2006; 46: 161-83.
[14]
Nirmala MJ, Samundeeswari A, Sankar PD. Natural plant resources in anti-cancer therapy-A review. Res Plant Biol 2011; 1(3): 1-14.
[15]
Channing J, Paller MD, Samuel R, et al. Challenges of conducting clinical trials of natural products to combat cancer. Clin Adv Hematol Oncol 2016; 14(6): 447-55.
[16]
Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75(3): 311-35.
[17]
Amin AR, Kucuk O, Khuri FR, et al. Perspectives for cancer prevention with natural compounds. J Clin Oncol 2009; 27: 2712-25.
[18]
Ishikawa H, Saeki T, Otani T, et al. Aged garlic extract prevents a decline of NK cell number and activity in patients with advanced cancer. J Nutr 2006; 136: 816S-20S.
[19]
Tanaka Sh, Haruma K, Yoshihara M, et al. Aged garlic extract has potential suppressive effect on colorectal adenomas in humans. J Nutr 2006; 136: 821S-6S.
[20]
Natelson EA, Giovanella BC, Verschraegen CF, et al. Phase I clinical and pharmacological studies of 20-(S)-camptothecin and 20-(S)-9-nitrocamptothecin as anticancer agents. Ann N Y Acad Sci 1996; 803: 224-30.
[21]
Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004; 10: 2319-26.
[22]
Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer CPT-11 gastrointestinal cancer study group. J Clin Oncol 1993; 11: 909-13.
[23]
Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemo-preventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001; 21: 2895-900.
[24]
Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14: 4491-9.
[25]
Bettuzzi S, Brausi M. Rizzi Federica, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-40.
[26]
Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004; 108: 130-5.
[27]
Gao YT, McLaughlin JK, Blot WJ, et al. Reduced risk of esophageal cancer associated with green tea consumption. J Natl Cancer Inst 1994; 86: 855-8.
[28]
Ji BT, Chow WH, Hsing AW. Green tea consumption and the risk of pancreatic and colorectal cancers. Int J Cancer 1997; 27: 255-8.
[29]
Choan E, Segal R, Jonker D, et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach. Urol Oncol 2005; 23: 108-13.
[30]
Kim JH, Park CY. Effects of Sun Ginseng on subjective quality of life in cancer patients: A double-blind, placebo-controlled pilot trial. J Clin Pharm Ther 2006; 31: 331-4.
[31]
Suh SO, Kroh M, Kim NR, et al. Effects of red ginseng upon postoperative immunity and survival in patients with stage III gastric cancer. Am J Chin Med 2002; 30: 483-94.
[32]
Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005; 100: 72-9.
[33]
Okouneva T, Hill BT, Wilson L, et al. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2003; 2: 427-36.
[34]
Simoens C, Lardon F, Pauwels B, et al. Comparative study of the radiosensitising and cell cycle effects of vinflunine and vinorelbine In-vitro. BMC Cancer 2008; 8(65): 1-12.
[35]
Shoeb M, MacManus SM, Jaspars M, et al. Montamine, a unique dimeric indole alkaloid, from the seeds of Centaurea montana (Asteraceae), and its in-vitro cytotoxic activity against the CaCo2 colon cancer cells. Tetrahedron 2006; 62: 11172-7.
[36]
Lee KH, Xiao Z. Podophyllotoxins and analogs In Anticancer Agents from Natural Products, edited by Cragg GM, Kingston DGI, Newman DJ Brunner-Routledge Psychology Press Taylor & Francis Group, Boca Raton; 2005; pp 71
[37]
Kingston DGI. The shape of things to come: Structural and synthetic studies of taxol and related compounds. Phytochemistry 2007; 68(14): 1844-54.
[38]
Hait WN, Rubin E, Alli E, et al. Tubulin targeting agents. Update Cancer Ther 2007; 2: 1-18.
[39]
Srivastava V, Negi AS, Kumar JK, et al. Plant-based anticancer molecules: A chemical and biological profile of some important leads. Bioorg Med Chem 2005; 13: 5892-8.
[40]
Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. J Clin Oncol 1996; 14: 3056-61.
[41]
Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32: 491-3.
[42]
Mineko I, Michio I, Ikuo M, et al. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC- 6. Anticancer Drugs 2000; 11: 353-62.
[43]
Reichardt P, Nielsen OS, Bauer S, et al. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II – study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2007; 43: 1017-22.
[44]
Zhang JA, Xuan T, Parmar M, et al. Development and characterization of a novel liposome-based formulation of SN-38. Int J Pharm 2004; 270: 93-107.
[45]
Cao Z, Kozielski A, Liu X, et al. Crystalline camptothecin-20(s)-opropionate hydrate: A novel anticancer agent with strong activity against 19 human tumor xenografts. Cancer Res 2009; 69: 4742-9.
[46]
Xie J, Ma T, Gu Y, et al. Berbamine derivatives: A novel class of compounds for anti-leukemia activity. Eur J Med Chem 2009; 44: 3293-8.
[47]
Xu R, Dong Q, Yu Y, et al. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006; 30: 17-23.
[48]
Wang F, Gao Y, Gao L, et al. Study on the electrochemical behavior of the anticancer herbal drug berberine and its analytical application. J Chin Chem Soc 2011; 58(4): 450-6.
[49]
Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol 2010; 645: 70-8.
[50]
Li Y, Li CJ, Yu D, et al. Potent induction of apoptosis by β- lapachone in human multiple myeloma cell lines and patient cells. Mol Med 2000; 6: 1008-15.
[51]
De Almeida ER. Preclinical and clinical studies of lapachol and betalapachone. Open Nat Prod J 2009; 2: 42-7.
[52]
Jeong SY, Park SJ, Yoon SM, et al. Systemic delivery and preclinical evaluation of Au nanoparticle containing β-lapachone for radiosensitization. J Control Release 2009; 139: 239-45.
[53]
Fulda S. Betulinic acid for cancer treatment and prevention. Int J Mol Sci 2008; 9: 1096-107.
[54]
Liaoo LL, Kupchan SM, Horwitz SB. Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis. Mol Pharmacol 1976; 12: 167-76.
[55]
Dubey KK, Ray AR, Behera BK. Production of demethylated colchicines through microbial transformation and scale-up process development. Process Biochem 2008; 43: 251-7.
[56]
Thomson P, Naylor MA, Everett SA, et al. Synthesis and biological properties of bioreductively targeted nitrothienyl pro Ley drugs of combretastatin A-4. Mol Cancer Ther 2006; 5: 2886-94.
[57]
Ley CD, Horsmany MR, Kristjansen PEG. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia 2007; 9: 108-12.
[58]
Molavi O, Ma Z, Mahmud A, Alshamsan A. Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. Int J Pharm 2008; 347: 118-27.
[59]
Bernard SA, Olayinka OA. Search for a novel antioxidant, anti-inflammatory / analgesic or antiproliferative drug: cucurbitacins hold the ace. J Med Plants Res 2010; 4: 2821-6.
[60]
Sa G, Das T, Banerjee S, et al. Curcumin: From exotic spice to modern anticancer drug. Al Ameen J Med Sci 2010; 3: 21-7.
[61]
Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as “Curecumin”: from kitchen to clinic. Biochem Pharmacol 2008; 75: 787-9.
[62]
Surh YJ, Chun KS. Cancer chemopreventive effects of curcumin In: Aggarwal BB, Surh YJ, Shishodia S, Eds The Molecular Targets and Therapeutic Uses of Urcumin in Health and Disease London: Springer; 2007 pp 149-72
[63]
Kim S, Hwang BY, Su BN, et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res 2007; 27: 2175-83.
[64]
Lu CL, Li YM, Fu GQ, et al. Extraction optimisation of daphnoretin from root bark of Wikstroemia indica (L) CA and its antitumour activity tests. Food Chem 2011; 124: 1500-6.
[65]
Diogo CV, Felix L, Vilela S, et al. Mitochondrial toxicity of the phyotochemicals daphnetoxin and daphnoretin-relevance for possible anti-cancer application. Toxicol In Vitro 2009; 23: 772-9.
[66]
Kaufman PB, Duke JA, Brielmann H, et al. A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health. J Altern Compl Med Spring 1997; 3: 7-12.
[67]
Moon YJ, Wang X, Morris ME. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 2006; 20: 187-210.
[68]
Dixon RA, Ferreira D. Molecules of interest: Genistein. Phytochemistry 2002; 60: 205-11.
[69]
Kuo YC, Kuo PL, Hsu YL, et al. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci 2006; 78: 2550-7.
[70]
Huang Z, Chen G, Shi P. Effects of emodin on the gene expression profiling of human breast carcinoma cells. Cancer Detect Prev 2009; 32: 286-91.
[71]
Mans DRA, Da Rocha AB, Schwartsmann G. Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist 2000; 5: 185-98.
[72]
Smith ME, Cimica V, Chinni S, et al. Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 2008; 14: 523-32.
[73]
Efferth T, Li PCH, Konkimalla VSB, et al. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007; 13: 353-61.
[74]
Nam S, Buettner R, Turkson J, et al. Indirubin derivatives inhibit Stat 3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 2005; 102: 5998-6003.
[75]
Liu XM, Wung LG, Li HY, et al. Induction of differentiation and downregulation of c-myb gene expression in ML4 human myeloblastic leukemia cells by the clinically effective and leukemia agent meisoindigo. Biochem Pharmacol 1996; 51: 1545-51.
[76]
Hampson P, Wang K, Lord JM. Treatment of actinic keratoses, acute myeloid leukemia therapy, Treatment of basal cell carcinoma, Protein kinase C activator. Drugs Future 2005; 30: 1003.
[77]
Hazra B, Sarma MD, Sanyal U. Separation methods of quinonoid constituents of plants used in oriental traditional medicines. J Chromatogr B 2004; 812: 259-75.
[78]
Herst PM, Davis JE, Neeson P, et al. The anticancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells. Haematologica 2009; 94: 928-34.
[79]
Pan L, Chai H, Kinghom AD. The continuing search for antitumor agents from higher plants. Phytochem Lett 2010; 3: 1-8.
[80]
Bardona S, Foussard V, Fournel S, et al. Monoterpenes inhibit proliferation of human colon cancer cells by modulating cell cycle-related protein expression. Cancer Lett 2002; 181: 187-94.
[81]
Yeruva L, Pierre KJ, Elegbede A, et al. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 2007; 257: 216-26.
[82]
Mi Q, Cui B, Silva GL, et al. Pervilleines A: A novel tropane alkaloid that reverses the multidrugresistance phenotype. Cancer Res 2001; 61: 4030-7.
[83]
Mi Q, Cui B, Silva GL, et al. Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay. Cancer Lett 2002; 184: 13-20.
[84]
Mi Q, Cui B, Lantvit D, et al. Pervilleine F: A new tropane alkaloid aromatic ester that reverses multidrug resistance. Anticancer Res 2003; 23: 3607-15.
[85]
Deng F, Lu JJ, Liu HY, et al. Synthesis and antitumor activity of novel salvicine analogues. Chin Chem Lett 2011; 22: 25-8.
[86]
Shoeb M, Celik S, Jaspars M, et al. Isolation, structure elucidation and bioactivity of schischkiniin, a unique indole alkaloid from the seeds of Centaurea schischkinii. Tetrahedro 2005; 61: 9001-6.
[87]
Kinghorn D, de Blanco EJC, Chai HB, et al. Discovery of anticancer agents of diverse natural origin. Pure Appl Chem 2009; 81: 1051-63.
[88]
Kim JH, Xu C, Keum YS, et al. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis 2006; 27: 475-82.
[89]
Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 2011; 11: 377-83.
[90]
Ancuceanu RV, Istudor V. Pharmacologically active natural compounds for lung cancer. Altern Med Rev 2004; 9: 402-19.
[91]
Helong L, Liangxing T, Yongxin Z, et al. Improved bioavailability and antitumor effect of docetaxel by TPGS modified proniosomes: In Vitro and In Vivo evaluations. Sci Rep 2017; 43372: 1-11.
[92]
Abir KP, Dwaipayan C, Irene S, et al. New insights into therapeutic activity and anticancer properties of curcumin. J Exp Pharmacol 2017; 9: 31-45.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2019
Page: [37 - 49]
Pages: 13
DOI: 10.2174/1573394714666180321151315
Price: $58

Article Metrics

PDF: 66
HTML: 2